Form 4 for CYRX Cryoport, Inc.
Accepted 2024-03-19 00:00:00 ET · period of report 2024-03-09 · accession 0001104659-24-036281 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2024-03-19 | 2024-03-11+ | CYRX | SHELTON JERRELL | Pres, CEO, Dir | S - Sale+OE | $15.37 | -60.8K | 637.0K | -9% | -$933.7K |
| DM | 2024-03-19 | 2024-03-09+ | CYRX | SHELTON JERRELL | Pres, CEO, Dir | M - OptEx | $4.43 | +108.2K | 640.7K | +20% | +$480.0K |
| D | 2024-03-19 | 2024-03-15 | CYRX | SHELTON JERRELL | Pres, CEO, Dir | A - Grant | $0.00 | +14.9K | 649.3K | +2% | $0 |
| D | 2024-03-19 | 2024-03-15 | CYRX | SHELTON JERRELL | Pres, CEO, Dir | A - Grant | $0.00 | +33.5K | 33.5K | New | $0 |
| DM | 2024-03-19 | 2024-03-09+ | CYRX | SHELTON JERRELL | Pres, CEO, Dir | M - OptEx | $0.00 | -108.2K | 4,167 | -96% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-03-15 | S | D | 54,440 | $15.04 | 694,813 | D | — | — | (F4) The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.84 to $15.28, inclusive. The reporting person undertakes to provide to Cryoport, Inc., any security holder of Cryoport, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 2 | Common | Common Stock | 2024-03-15 | M | A | 100,000 | $4.80 | 749,253 | D | — | — | |
| 3 | Common | Common Stock | 2024-03-15 | A | A | 14,901 | $0.00 | 649,253 | D | — | — | (F3) Represents restricted stock rights, which are a contingent right to receive one share of CYRX common stock, that vest in four equal annual installments beginning March 15, 2025. |
| 4 | Common | Common Stock | 2024-03-15 | S | D | 2,599 | $20.79 | 634,352 | D | — | — | |
| 5 | Common | Common Stock | 2024-03-09 | M | A | 8,250 | $0.00 | 640,674 | D | — | — | (F1) Represents the conversion of restricted stock rights to shares of common stock upon vesting. Each restricted stock right represents a contingent right to receive one share of CYRX common stock. |
| 6 | Common | Common Stock | 2024-03-11 | S | D | 3,723 | $16.35 | 636,951 | D | — | — | |
| 7 | Derivative | Stock Option (right to buy) | 2024-03-15 | A | A | 33,524 | $0.00 | 33,524 | D | $16.70 · — to 2031-03-15 | 33,524 Common Stock | (F7) 1/48 of options vest on the 15th of each month for forty-eight months beginning April 25, 2024. |
| 8 | Derivative | Restricted Stock Rights | 2024-03-09 | M | D | 8,250 | $0.00 | 8,250 | D | — · — to — | 8,250 Common Stock | (F5) The originally granted restricted stock rights vest in four equal annual installments beginning 3/9/2022, and have no expiration date. The restricted stock rights reported herein vested and converted to shares of CYRX common stock on a one-for-one basis on March 9, 2024. |
| 9 | Derivative | Stock Option (right to buy) | 2024-03-15 | M | D | 100,000 | $0.00 | 4,167 | D | $4.80 · — to 2024-12-18 | 100,000 Common Stock | (F6) 1/48 of the options vested on the 18th of each month for forty-eight months beginning on January 18, 2015. |